Skip to main content
      RT @Stiddyo: #OP0229 GRAPPA recommendations crisply presented by @DrLauraCoates
      Importantly it needs to be tailored to

      Paul Studenic Stiddyo

      3 years 6 months ago
      #OP0229 GRAPPA recommendations crisply presented by @DrLauraCoates Importantly it needs to be tailored to the patient taking amongst under comorbidities and the heterogeneity of features of the clinical presentation into account. #EULAR2021 @RheumNow https://t.co/MpZGzhq0Ic
      RT @Stiddyo: #OP0231 BADBIR register (incl. Ustekinumab & csDMARD treated patients) 2697 PsO without PsA & 590 P

      Paul Studenic Stiddyo

      3 years 6 months ago
      #OP0231 BADBIR register (incl. Ustekinumab & csDMARD treated patients) 2697 PsO without PsA & 590 PsO with PsA: obesity, diabetes, hypetension and inabililty to work was more likely in Pso patients with PsA than patients with PsO alone #EULAR2021 @RheumNow
      RT @Stiddyo: #OP0233 In SELECT-PsA1 & 2 analyses for PsA with axial involvement: 31% / 34% of the studies populatio

      Paul Studenic Stiddyo

      3 years 6 months ago
      #OP0233 In SELECT-PsA1 & 2 analyses for PsA with axial involvement: 31% / 34% of the studies population: > Improvement of axial symptoms on upadacitinib across several outcomes compared to PLC! > 1new onset of uveitis on upadacitinib #EULAR2021 @RheumNow https://t.co/9YK1OYEorq
      RT @Stiddyo: Dr. Gladman highlighted the full spectrum of #PsA in today's #EULAR2021 afternoon session.

      "-> All doma

      Paul Studenic Stiddyo

      3 years 6 months ago
      Dr. Gladman highlighted the full spectrum of #PsA in today's #EULAR2021 afternoon session. "-> All domains need to be assessed in our psa patients! -> Its interesting that we have not been able to identify genetic dispositions to particular features " @RheumNow
      RT @Yuz6Yusof: Does clinical response equate good #HRQoL in #SLE? Dr Gomez analysed responders in #belimumab trials and

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 6 months ago
      Does clinical response equate good #HRQoL in #SLE? Dr Gomez analysed responders in #belimumab trials and showed up to 29% pts reported poor SF-36 (esp physical aspects). Physical functioning & fatigue improved with therapy #EULAR2021 #POS0101 @RheumNow https://t.co/IU1k0UetEx
      RT @Yuz6Yusof: Is there a need to routinely monitor #ANA in patients treated on #TNF inhibitors? The jury👨‍⚖️is

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 6 months ago
      Is there a need to routinely monitor #ANA in patients treated on #TNF inhibitors? The jury👨‍⚖️is still out. Of N=211, Dr Oliveira reported 75.4% had seroconversion at median 31mths of TNFi therapy. Only 2/211 (0.9%) developed SLE (mild symptoms) #EULAR2021 #POS0204 @RheumNow https://t.co/UrFucJ9xnJ
      RT @Yuz6Yusof: #MachineLearning to unravel pathways associated with #SLE. Dr Morand analysed N=1760 pts from RCTs. Using

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 6 months ago
      #MachineLearning to unravel pathways associated with #SLE. Dr Morand analysed N=1760 pts from RCTs. Using deep learning algorithms, they identified novel pathways (CD4 Tcell Differentiation, Macrophage and DCs) in addition to known #IFN and #JAKSTAT #EULAR2021 #POS0351 @RheumNow https://t.co/Gc7zL8JQZe
      RT @Yuz6Yusof: #Interferon as biomarkers in #RMD? Dr Burska on behalf of #EULAR TF reported heterogeneity in published p

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 6 months ago
      #Interferon as biomarkers in #RMD? Dr Burska on behalf of #EULAR TF reported heterogeneity in published papers re:IFN-I pathway activation assays, hence unable to perform meta-analyses of results.They proposed Consensus Terminology for IFN #research #EULAR2021 #POS0370 @RheumNow https://t.co/lbqy2xbEyt
      RT @Yuz6Yusof: In a UK study of newly diagnosed #SLE (within 12 months of meeting ACR criteria), Dr Yee reported BILAG-2

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 6 months ago
      In a UK study of newly diagnosed #SLE (within 12 months of meeting ACR criteria), Dr Yee reported BILAG-2004 Grade A or B was predictive of damage in the median FU of 73 months. MMF use appeared to be protective #EULAR2021 #POS0705 @RheumNow https://t.co/VROqTTrzwY
      RT @Yuz6Yusof: Is efficacy of #voclosporin in #lupus nephritis sustained at 2 years? N=116 pts on VOC and N=100 pts on P

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 6 months ago
      Is efficacy of #voclosporin in #lupus nephritis sustained at 2 years? N=116 pts on VOC and N=100 pts on Placebo enrolled in Extension Study. Dr Saxena reported patients on VOC continued meaningful ⬇️in uPCR and stable eGFR up to 2yrs vs Placebo #EULAR2021 #POS0681 @RheumNow https://t.co/M5MX7tW2CA
      RT @chriswincup: Still time to sign up for a place in today’s #lupus interest group at #EULAR2021 (last few spaces re

      Chris Wincup chriswincup

      3 years 6 months ago
      Still time to sign up for a place in today’s #lupus interest group at #EULAR2021 (last few spaces remaining) 🕒12:30 CEST / 11:30 UK 🧬 "Lupus, the next 10 years" 🔬where we will be joined by @edvital 📍Click EULAR Networking then Interest Group Discussion to join @EMEUNET https://t.co/6r7RYOi8VG
      RT @Yuz6Yusof: Once approved, in what type of patients with #psoriaticarthritis would you treat with IL23-inhibitors? #E

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 6 months ago
      Once approved, in what type of patients with #psoriaticarthritis would you treat with IL23-inhibitors? #EULAR2021 #OP0228 #OP0230 @RheumNow 🤔
      RT @Yuz6Yusof: #Lupus Interest Group Meeting #EULAR2021. Working towards personalised medicine to improve treatment of o

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 6 months ago
      #Lupus Interest Group Meeting #EULAR2021. Working towards personalised medicine to improve treatment of our patients with lupus. Future of #SLE research are in good hands 👌#NEXTGEN @edvital @GeorgeARobinson @pekor002 @dalilatm Matteo Boemi, Teona @eular_org https://t.co/eK4oiwlJZO
      RT @Yuz6Yusof: Utility of salivary gland biopsy in #Sjogren?Dr Chatzis analysed biopsy from N=618 with =>1 yr FU befo

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 6 months ago
      Utility of salivary gland biopsy in #Sjogren?Dr Chatzis analysed biopsy from N=618 with =>1 yr FU before 🔼lymphoma. 58/618 developed lymphoma. Predictors identified were⬆️Focus Score, cryoglobulin & parotid swelling. FS=>4 predicted earlier lymphoma #EULAR2021 #OP0291 @RheumNow https://t.co/yFFZpBRvji
      RT @KDAO2011: In case you're not convinced:
      Another study showed HCQ protects SLE pts from death. Risk reduction in thos

      k dao KDAO2011

      3 years 6 months ago
      In case you're not convinced: Another study showed HCQ protects SLE pts from death. Risk reduction in those taking antimalarials 83% vs. those who cannot take the drug (for any reason) 42%, yet 60% of patients are non-adherent -study reviewed by Prof Dorner #EULAR2021 @rheumnow https://t.co/zBgCLipHPP
      ×